Divergent Technologies: Scaling AI-Driven 3D Manufacturing
This Week in Startupsgo watch the original →
the gist
Lukas Czinger explains how Divergent Technologies uses AI-driven design and proprietary 3D printing to manufacture complex metal structures for defense and automotive industries at scale.
The Shift to Digital Manufacturing
Lukas Czinger, CEO of Divergent Technologies, describes a transition from traditional, labor-intensive manufacturing to a software-defined, AI-driven platform. The company treats manufacturing like a server farm: they use AI to generate optimized designs, print them using proprietary alloys and 3D printers, and assemble them with robotics. This approach allows them to be product-agnostic, switching between automotive chassis and cruise missile airframes on the same hardware.
Scaling Additive Manufacturing
Historically, 3D printing was relegated to prototyping due to slow speeds and high costs. Czinger notes that productivity has increased more than 10x in the last decade. For defense applications, their systems can produce thousands of complex metal airframes annually. By treating factories as modular, replicable units—similar to AWS data centers—they can distribute production geographically and surge capacity based on demand, effectively creating a "copy-paste" model for industrial manufacturing.
Defense and Commercial Integration
Unlike companies that sell 3D printers, Divergent operates as a vertically integrated tier-one supplier. They handle the entire stack: engineering, material chemistry, printing, and assembly. This allows them to meet the stringent certification requirements of the US military. By maintaining a mix of commercial and defense work, they ensure that their production lines remain active and adaptable, solving the "munitions crisis" by providing high-volume, affordable mass-production capabilities for sophisticated systems.
The SSRI Tapering Crisis
In a separate segment, Brandon Goode and Dr. Mark Horowitz discuss the dangers of abrupt SSRI withdrawal. They argue that the "chemical imbalance" theory of depression is often a marketing construct used by pharmaceutical companies. They advocate for "hyperbolic tapering"—a method of reducing dosage in smaller, more frequent increments as the brain adapts—to help patients safely discontinue long-term antidepressant use without suffering severe withdrawal symptoms.